1. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev. 2011; 20:287–296.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Kucera E, Sliutz G, Czerwenka K, Breitenecker G, Leodolter S, Reinthaller A. Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone? Eur J Obstet Gynecol Reprod Biol. 2001; 100:72–76.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer. 2006; 118:2048–2055.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst. 2009; 101:721–728.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev. 2004; 30:205–211.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Prato B, Ghelardi A, Gadducci A, Marchetti I, Di Cristofano C, Di Coscio G, et al. Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. Int J Gynecol Cancer. 2008; 18:90–94.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Ronco G, Sideri MG, Ciatto S. Cervical intraepithelial neoplasia and higher long term risk of cancer. BMJ. 2007; 335:1053–1054.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Paraskevaidis E, Koliopoulos G, Alamanos Y, Malamou-Mitsi V, Lolis ED, Kitchener HC. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol. 2001; 98:833–836.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Sarian LO, Derchain SF, Pitta DR, Morais SS, Rabelo-Santos SH. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). J Clin Virol. 2004; 31:270–274.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Baser E, Ozgu E, Erkilinc S, Togrul C, Caglar M, Gungor T. Risk factors for human papillomavirus persistence among women undergoing cold-knife conization for treatment of high-grade cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2014; 125:275–278.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Serati M, Siesto G, Carollo S, Formenti G, Riva C, Cromi A, et al. Risk factors for cervical intraepithelial neoplasia recurrence after conization: a 10-year study. Eur J Obstet Gynecol Reprod Biol. 2012; 165:86–90.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Livasy CA, Maygarden SJ, Rajaratnam CT, Novotny DB. Predictors of recurrent dysplasia after a cervical loop electrocautery excision procedure for CIN-3: a study of margin, endocervical gland, and quadrant involvement. Mod Pathol. 1999; 12:233–238.
13. Lu CH, Liu FS, Tseng JJ, Ho ES. Predictive factors for residual disease in subsequent hysterectomy following conization for CIN III. Gynecol Oncol. 2000; 79:284–288.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol. 2003; 90:358–365.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Dugué PA, Rebolj M, Garred P, Lynge E. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther. 2013; 13:29–42.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001; 8:209–220.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Guzmán-Olea E, Bermúdez-Morales VH, Peralta-Zaragoza O, Torres-Poveda K, Madrid-Marina V. Molecular mechanism and potential targets for blocking HPV-induced lesion development. J Oncol. 2012; 2012:278312.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Nguyen HH, Broker TR, Chow LT, Alvarez RD, Vu HL, Andrasi J, et al. Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol. 2005; 96:452–461.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res. 2009; 15:6341–6347.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Yang W, Song Y, Lu YL, Sun JZ, Wang HW. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology. 2013; 139:513–522.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Kojima S, Kawana K, Tomio K, Yamashita A, Taguchi A, Miura S, et al. The prevalence of cervical regulatory T cells in HPV-related cervical intraepithelial neoplasia (CIN) correlates inversely with spontaneous regression of CIN. Am J Reprod Immunol. 2013; 69:134–141.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Kurman RJ. International Agency for Research on Cancer. World Health Organization. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer;2014.
23. Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016; 29:1165–1172.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res. 2017; 5:12.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987; 8:138–140.
26. Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Campo E, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol. 2006; 103:631–636.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2010; CD001318.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Lu CH, Liu FS, Kuo CJ, Chang CC, Ho ES. Prediction of persistence or recurrence after conization for cervical intraepithelial neoplasia III. Obstet Gynecol. 2006; 107:830–835.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Tillmanns TD, Falkner CA, Engle DB, Wan JY, Mannel RS, Walker JL, et al. Preoperative predictors of positive margins after loop electrosurgical excisional procedure-Cone. Gynecol Oncol. 2006; 100:379–384.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Paraskevaidis E, Lolis ED, Koliopoulos G, Alamanos Y, Fotiou S, Kitchener HC. Cervical intraepithelial neoplasia outcomes after large loop excision with clear margins. Obstet Gynecol. 2000; 95:828–831.
![crossref](/image/icon/bnr_ref_cross.gif)
31. Leguevaque P, Motton S, Decharme A, Soulé-Tholy M, Escourrou G, Hoff J. Predictors of recurrence in high-grade cervical lesions and a plan of management. Eur J Surg Oncol. 2010; 36:1073–1079.
![crossref](/image/icon/bnr_ref_cross.gif)
32. Macgregor JE, Campbell MK, Mann EM, Swanson KY. Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease. BMJ. 1994; 308:1407–1411.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Lin H, Chang HY, Huang CC, Changchien CC. Prediction of disease persistence after conization for microinvasive cervical carcinoma and cervical intraepithelial neoplasia grade 3. Int J Gynecol Cancer. 2004; 14:311–316.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Park JY, Lee KH, Dong SM, Kang S, Park SY, Seo SS. The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. Gynecol Oncol. 2008; 108:549–554.
![crossref](/image/icon/bnr_ref_cross.gif)
35. Ghaem-Maghami S, Sagi S, Majeed G, Soutter WP. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncol. 2007; 8:985–993.
![crossref](/image/icon/bnr_ref_cross.gif)
36. Oliveira CA, Russomano FB, Gomes Júnior SC, Corrêa FM. Risk of persistent high-grade squamous intraepithelial lesion after electrosurgical excisional treatment with positive margins: a meta-analysis. Sao Paulo Med J. 2012; 130:119–125.
![crossref](/image/icon/bnr_ref_cross.gif)
37. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677–704.
![crossref](/image/icon/bnr_ref_cross.gif)
38. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012; 2012:656340.
![crossref](/image/icon/bnr_ref_cross.gif)
39. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015; 15:45–56.
40. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005; 11:2947–2953.
![crossref](/image/icon/bnr_ref_cross.gif)
41. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007; 13:2151–2157.
![crossref](/image/icon/bnr_ref_cross.gif)
42. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007; 104:3360–3365.
![crossref](/image/icon/bnr_ref_cross.gif)
43. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15:971–979.
![crossref](/image/icon/bnr_ref_cross.gif)
44. Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, van der Velden J, Kenter GG, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016; 29:753–763.
![crossref](/image/icon/bnr_ref_cross.gif)
45. Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, et al. Epithelial PD-L2 expression marks Barrett’s esophagus and esophageal adenocarcinoma. Cancer Immunol Res. 2015; 3:1123–1129.
![crossref](/image/icon/bnr_ref_cross.gif)
46. Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015; 28:1594–1602.
![crossref](/image/icon/bnr_ref_cross.gif)
47. Zhang H, Zhang T, You Z, Zhang Y. Positive surgical margin, HPV persistence, and expression of both TPX2 and PD-L1 are associated with persistence/recurrence of cervical intraepithelial neoplasia after cervical conization. PLoS One. 2015; 10:e0142868.
![crossref](/image/icon/bnr_ref_cross.gif)
48. Chang H, Kim JS, Choi YJ, Cho JG, Woo JS, Kim A, et al. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther. 2017; 10:2983–2992.
![crossref](/image/icon/bnr_ref_cross.gif)